Repligen Corp
- Last sale
- Nov 12, 2026 · -3.49%
- Market cap
- $10.65B
- 63.92M shares
- Filings
- 1,040
Q3 2026+16.4% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derived−37.3% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−25.3% FY25 yoy
- $10.65B
- —
- 13.2×
- 5.1×
- 1.00%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $738,256,000 | reported | |
| FY 2024 | 2024-12-31 | $634,439,000 | reported | |
| FY 2023 | 2023-12-31 | $632,362,000 revised | reported | |
| FY 2022 | 2022-12-31 | $801,536,000 revised | reported | |
| FY 2021 | 2021-12-31 | $670,534,000 | reported | |
| FY 2020 | 2020-12-31 | $366,260,000 | reported | |
| FY 2019 | 2019-12-31 | $270,245,000 | reported | |
| FY 2018 | 2018-12-31 | $194,032,000 | reported | |
| FY 2017 | 2017-12-31 | $141,236,000 | reported | |
| FY 2016 | 2016-12-31 | $104,541,000 | reported | |
| FY 2015 | 2015-12-31 | $83,537,000 | reported | |
| FY 2014 | 2014-12-31 | $63,548,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $0.00 | $0.00 | — | 56.33M sh | +0.3% | 0.0% |
| FY2024 | — | $0.00 | $0.00 | — | 56.15M sh | +0.7% | 0.0% |
| FY2023 | — | $14.39M | $14.39M | — | 55.77M sh | +0.4% | 18.5% |
| FY2022 | — | $0.00 | $0.00 | — | 55.56M sh | +0.4% | 0.0% |
| FY2021 | — | $0.00 | $0.00 | — | 55.33M sh | +1.0% | 0.0% |
Segments
LineFY2025ShareChange
North America$2.34B79%+1.5%
Europe$489.93M17%+19.4%
APAC$119.59M4.1%+5.1%
Total$2.95B
Biological products, except diagnostic substances
Repligen Corp is the 12th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
TECHBio-Techne Corp$1.2B0.4%15.0%$11.4BNVAXNovavax Inc$1.1B64.7%39.2%$1.4BBCRXBiocryst Pharmaceuticals Inc$874.8M94.1%30.2%$2.0B
RGENRepligen Corp (this company)$738.3M16.4%6.6%$10.7B
ALVOAlvotech$586.3M19.7%4.8%$1.5BADMAAdma Biologics, Inc.$510.2M19.6%28.8%$2.9BTWSTTwist Bioscience Corp$459.4M22.0%28.3%$7.8BTARSTarsus Pharmaceuticals, Inc.$451.4M146.7%14.7%$3.8BIMCRImmunocore Holdings plc$400.0M29.0%8.9%$1.6BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Repligen Corp · CIK 730272 · Engraved from SEC EDGAR